US 11,980,689 B2
Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH)
Mark William Surber, San Diego, CA (US)
Assigned to AVALYN PHARMA INC., Seattle, WA (US)
Filed by AVALYN PHARMA INC., Seattle, WA (US)
Filed on Sep. 22, 2020, as Appl. No. 17/028,630.
Application 17/028,630 is a division of application No. 14/449,066, filed on Jul. 31, 2014, abandoned.
Claims priority of provisional application 61/948,461, filed on Mar. 5, 2014.
Claims priority of provisional application 61/860,721, filed on Jul. 31, 2013.
Prior Publication US 2021/0093570 A1, Apr. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/14 (2006.01); A61K 9/00 (2006.01); A61K 31/506 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61P 11/00 (2006.01)
CPC A61K 9/14 (2013.01) [A61K 9/0075 (2013.01); A61K 9/0078 (2013.01); A61K 9/008 (2013.01); A61K 31/506 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01)] 12 Claims
 
1. A method to treat pulmonary arterial hypertension in a human patient by inhaled delivery of aerosolized imatinib compound comprising
administering to the patient a daily unit dose of an aerosol of the imatinib compound that is not encapsulated and is contained in a device for aerosol delivery of particles having a mean volumetric diameter between about 2 and about 4 microns, wherein the daily inhaled dose of imatinib is from 4 mg to 100 mg, and
obtaining a blood Cmax following aerosol delivery of the daily unit dose of less than 10 mcg/ml to achieve a therapeutically effective amount to alleviate pulmonary arterial hypertension.